References
- Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4
- Copeland RA. 2000. Enzymes: a practical introduction to structure, mechanism, and data analysis. New York: Wiley-VCH, Inc
- Florea NR, Capitano B, Nightingale CH, et al. (2003). Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 35:2873–7
- Haria M, Bryson HM, Goa KL. (1996). Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585–620
- Heykants J, van Peer A, van de Velde V, et al. (1989). The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32(Suppl 1):67–87
- Isoherranen N, Kunze KL, Allen KE, et al. (2004). Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121–31
- Krasulova K, Siller M, Holas O, et al. (2016). Enantiospecific effects of chiral drugs on cytochrome P450 inhibition in vitro. Xenobiotica 46:315–24
- Kunze KL, Nelson WL, Kharasch ED, et al. (2006). Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 34:583–90
- Kurka O, Kucera L, Bednar P. (2016). Analytical and semipreparative chiral separation of cis-itraconazole on cellulose stationary phases by high-performance liquid chromatography. J Sep Sci 39:2736–45
- Liu JO, Chong CR, Xu J, et al. (2012). Chirally pure isomers of itraconazole for use as angiogenesis inhibitors
- Liu L, Bello A, Dresser MJ, et al. (2016). Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies. J Clin Pharmacol 56:143–51
- Lutz JD, Vandenbrink BM, Babu KN, et al. (2013). Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metab Dispos 41:2056–65
- Mahnke CB, Sutton RM, Venkataramanan R, et al. (2003). Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant 7:474–8
- Nett JE, Andes DR. (2016). Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin N Am 30:51–83
- Niwa T, Imagawa Y, Yamazaki H. (2014). Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab 15:651–79
- Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. (2005a). Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull 28:1813–16
- Niwa T, Shiraga T, Takagi A. (2005b). Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–8
- Novotna A, Krasulova K, Bartonkova I, et al. (2014). Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells. PLoS One 9:e111286
- Peng CC, Shi W, Lutz JD, et al. (2012). Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metab Dispos 40:426–35
- Phillips IR, Shephard EA. 2006. Cytochrome P450 protocols. Totowa (NJ): Humana Press
- Shin JG, Kane K, Flockhart DA. (2001). Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 51:45–52
- Smith SW. (2009). Chiral toxicology: it's the same thing…only different. Toxicol Sci 110:4–30
- Stepankova M, Pastorkova B, Bachleda P, Dvorak Z. (2017). Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes. Toxicology 383:40–9
- Templeton IE, Thummel KE, Kharasch ED, et al. (2008). Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77–85
- Vanden Bossche H, Marichal P, Gorrens J, et al. (1989). Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 32(Suppl 1):35–52
- Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111–80